DOI: https://dx.doi.org/10.18565/pharmateca.2022.6.37-46
Листратов А.И., Остроумова О.Д., Комарова А.Г.
1) Российская медицинская академия непрерывного профессионального образования, Москва, Россия; 2) Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет), Москва, Россия; 3) ГКБ им. С.П. Боткина ДЗМ, Москва, Россия
1. Клинические рекомендации. Мочекаменная болезнь. Минздрав России, Общероссийская общественная организация «Российское общество урологов». Пересмотр 2020 г. 2. Alelign T., Petros B. Kidney Stone Disease: An Update on Current Concepts. Adv Urol. 2018;2018:3068365. Doi: 10.1155/2018/3068365. 3. Daudon M., Frochot V., Bazin D., Jungers P. Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment. Drugs. 2018;78(2):163-201. Doi: 10.1007/s40265-017-0853-7. 4. DobrekL. Kidney stone disease with special regard to drug-induced kidney stones - a contemporary synopsis. Wiad Lek. 2020;73(9 cz. 2):2031-39. Doi: 10.36740/WLek202009226. 5. Ettinger B., Weil E., Mandel N.S., Darling S. Triamterene-induced nephrolithiasis. Ann Intern Med. 1979;91(5):745-46. Doi: 10.7326/00034819-91-5-745. 6. Ettinger B., Oldroyd N.O., Sorgel F. Triamterene nephrolithiasis. JAMA. 1980;244(21):2443-45. 7. Daudon M., Protat M.F., Re'veillaud R.J. Triamterene and renal calculi 8. Jick H., Dinan B.J., Hunter J.R. Triamterene and renal stones. J Urol. 1982;127(2):224-25. Doi: 10.1016/s0022-5347(17)53708-8. 9. Fairley K.F., Birch D.F., Haines I. Abnormal urinary sediment in patients on triamterene. Lancet. 1983;1(8321):421-22. Doi: 10.1016/s0140- 6736(83)91542-8. 10. Woolfson R.G., Mansell M.A. Does triamterene cause renal calculi? BMJ. 1991;303(6812):1217- 18. Doi: 10.1136/bmj.303.6812.1217. 11. Sorgel F, Ettinger B., Benet L.Z. The true composition of kidney stones passed during triamterene therapy. J Urol. 1985;134(5):871- 73. Doi: 10.1016/s0022-5347(17)47497-0. 12. Carey R.A., Beg M.M., McNally C.F., Tannenbaum P. Triamterene and renal lithiasis: a review. Clin Ther. 1984;6(3):302-9. 13. Sica D.A., Gehr T.W. Triamterene and the kidney. Nephron. 1989;51(4):454-61. Doi: 10.1159/000185375. 14. Spence J.D., Wong D.G., Lindsay R.M. Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide. Lancet. 1985;2(8446):73-5. Doi: 10.1016/ s0140-6736(85)90180-1. 15. Becker K., Jablonowski H., Haussinger D. Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Medicine (Baltimore). 1996;75(4):185-94. Doi: 10.1097/00005792-199607000-00002. 16. Izzedine H., Lescure F.X., Bonnet F. HIV medication-based urolithiasis. Clin Kidney J. 2014;7(2):121- 26. Doi: 10.1093/ckj/sfu008. 17. Guitard J., Kamar N., Mouzin M., et al. Sulfadiazine-related obstructive urinary tract lithiasis: an unusual cause of acute renal failure after kidney transplantation. Clin Nephrol. 2005;63(5):405-7. Doi: 10.5414/cnp63405. 18. Catalano-Pons C., Bargy S., Schlecht D., et al. Sulfadiazine-induced nephrolithiasis in children. Pediatr Nephrol. 2004;19(8):928-31. Doi: 10.1007/s00467-004-1519-8. 19. Kabha M., Dekalo S., Barnes S., et al. Sulfadiazine-Induced Obstructive Nephropathy Presenting with Upper Urinary Tract Extravasation. J Endourol Case Rep. 2016;2(1):159-61. Doi: 10.1089/ cren.2016.0093. 20. Roedel M.M., Nakada S.Y., Penniston K.L. Sulfamethoxazole-induced sulfamethoxazole urolithiasis: a case report. BMC. Urol. 2021;21(1):133. Doi:10.1186/s12894-021- 00894-5. 21. Yanagisawa R., Kamijo T., Nagase Y. A case of drug induced urolithiasis composed of acetyl sulphapyridine associated with ulcerative colitis 22. Otto H., Allesch V. Urinary concrements due to long-term sulfonamides 23. de Liso F., Garigali G., Ferraris Fusarini C., et al. How to identify sulfamethoxazole crystals in the urine. Clin Chim Acta. 2016;452:106-8. Doi: 10.1016/j.cca.2015.11.006. 24. Albala D.M., Prien E.L. Jr., Galal H.A. Urolithiasis as a hazard of sulfonamide therapy. J Endourol. 1994;8(6):401-3. Doi: 10.1089/ end.1994.8.401. 25. De Koninck A.S., Groen L.A., Maes H., et al. An Unusual Type of Kidney Stone. Clin. Lab. 2016;62(1-2):235-39. Doi: 10.7754/clin. lab.2015.150605. 26. Hasan M.N., Tiselius H.G. Mesalamine: a rare constituent of urinary tract concretions. Urolithias. 2013;41(3):271-72. Doi: 10.1007/s00240- 013-0553-z. 27. Daudon M., Re'veillaud R.J. Drug-induced crystalluria: myths and realities 28. Daudon M., Estepa L., Viard J.P., et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet. 1997;349(9061):1294-95. Doi: 10.1016/s0140-6736(05)62506-8. 29. Kopp J.B., Miller K.D., Mican J.A., et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127(2):119-25. Doi: 10.7326/0003-4819-127-2-19970715000004. 30. Boubaker K., Sudre P., Bally F., et al. Changes in renal function associated with indinavir. AIDS. 1998;12(18):F249-54. Doi: 10.1097/00002030-199818000-00003. 31. Herman J.S., Ives N.J., Nelson M., et al. Incidence and risk factors for the development of indinavir- associated renal complications. J Antimicrob Chemother. 2001;48(3):355-60. Doi: 10.1093/ jac/48.3.355. 32. Gulick R.M., Mellors J.W., Havlir D., et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133(1):35-9. Doi: 10.7326/0003-4819133-1-200007040-00007. 33. Saltel E., Angel J.B., Futter N.G., et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000;164(6):1895-97. 34. Daudon M., Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs. 2004;64(3):245-75. Doi: 10.2165/00003495-200464030-00003. 35. Daudon M., Estepa L., Viard J.P., et al. Indinavir crystalluria in HIV-positive patients treated with indinavir sulfate. In: Rodgers A.L., Hibbert B.E., Hess B., et al, editors. Urolithias. 2000;I:335-37. 36. Balani S.K., Arison B.H., Mathai L., et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos. 1995;23(2):266-70. 37. Hanabusa H., Tagami H., Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med. 1999;340(5):392-93. Doi: 10.1056/NEJM199902043400515. 38. Chen I.W., Vastag K.J., Lin J.H. High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. J Chromatogr B Biomed Appl. 1995;672(1):111-17. Doi: 10.1016/0378-4347(95)00191-k. 39. Tashima K.T., Horowitz J.D., Rosen S. Indinavir nephropathy. N Engl J Med. 1997;336(2):138- 40. Doi: 10.1056/NEJM199701093360215. 40. Reilly R.F., Tray K., Perazella M.A. Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis. 2001;38(4):E23. Doi: 10.1053/ ajkd.2001.27732. 41. Schwartz B.F., Schenkman N., Armenakas N.A, Stoller M.L. Imaging characteristics of indinavir calculi. J Urol. 1999;161(4):1085-87. 42. Pacanowski J., Poirier J.M., Petit I., et al. Atazanavir urinary stones in an HIV-infected patient. AIDS. 2006;20(16):2131. Doi: 10.1097/01. aids.0000247571.88256.90. 43. Anderson P.L., Lichtenstein K.A., Gerig N.E., et al. Atazanavir-containing renal calculi in an HIV- infected patient. AIDS. 2007;21(8):1060-62. Doi: 10.1097/QAD.0b013e3280c56ae1. 44. Moriyama Y., Minamidate Y., Yasuda M., et al. Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient. Urol Res. 2008;36(5):275-77. Doi: 10.1007/s00240- 008-0147-3. 45. Couzigou C., Daudon M., Meynard J.L., et al. Urolithiasis in HIVpositive patients treated with atazanavir. Clin Infect Dis. 2007;45(8):e105-8. Doi: 10.1086/521930. 46. Chan-Tack K.M., Truffa M.M., Struble K.A., Birnkrant D.B. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration’s Adverse Event Reporting System. AIDS. 2007;21(9):1215-18. Doi: 10.1097/ QAD.0b013e32813aee35. 47. Rockwood N., Mandalia S., Bower M., et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS. 2011;25(13):1671-63. Doi: 10.1097/ QAD.0b013e32834a1cd6. 48. Hamada Y., Nishijima T., Watanabe K., et al. High incidence of renal stones among HIV- infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitorcontaining antiretroviral therapy. Clin Infect. Dis. 2012;55(9):1262-69. Doi: 10.1093/cid/ cis621. 49. de Lastours V., Ferrari Rafael De Silva E., Daudon M., et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother. 2013;68(8):1850-56. Doi: 10.1093/jac/dkt125. 50. Lafaurie M., De Sousa B., Ponscarme D., et al. Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study. PLoS One. 2014;9(11):e112836. Doi: 10.1371/ journal.pone.0112836. 51. Smith D.E., Jeganathan S., Ray J. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV. Clin Trials. 2006;7(1):34-8. Doi: 10.1310/0KX0-H9VH-99EE-5D0L. 52. Johnson D.H., Venuto C., Ritchie M.D., et al. Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics. 2014;24(4):195- 203. Doi: 10.1097/FPC.0000000000000034. 53. Hirsch M.S., Steigbigel R.T., Staszewski S., et al. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor- naive adults with advanced HIV infection. Clin Infect Dis. 2003;37(8):1119-24. Doi: 10.1086/ 378063. 54. Feicke A., Rentsch K.M., Oertle D., Strebel R.T. Same patient, new stone composition: amprenavir urinary stone. Antivir Ther. 2008;13(5):733-34. 55. Doco-Lecompte T., Garrec A., Thomas L., et al. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS. 2004;18(4):705-6. Doi: 10.1097/00002030-200403050-00022. 56. Engeler D.S., John H., Rentsch K.M., et al. Nelfinavir urinary stones. J Urol. 2002;167(3):1384-85. 57. Barry M., Gibbons S., Back D., Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997;32(3):194-209. Doi: 10.2165/00003088-19973203000003. 58. Green S.T., McKendrick M.W., Schmid M.L., et al. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS. 1998;9(9):555. 59. Cicconi P., Bongiovanni M., Melzi S., et al. Nephrolithiasis and hydronephrosis in an HIV- infected man receiving tenofovir. Int J Antimicrob Agents. 2004;24(3):284-85. Doi: 10.1016/j. ijantimicag.2004.04.005. 60. Vassallo M., Dunais B., Naqvi A., et al. Raltegravir-induced nephrolithiasis: a case report. AIDS. 2012;26(10):1323-24. Doi: 10.1097/QAD.0b013e328353fda1. 61. Izzedine H., Valantin M.A., Daudon M., et al. Efavirenz urolithiasis. AIDS. 2007;21(14):1992. Doi: 10.1097/QAD.0b013e3282ef792f. 62. Maurice-Estepa L., Daudon M., Katlama C., et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis. 1998;32(3):392-400. Doi: 10.1053/ ajkd.1998.v32.pm9740154. 63. Becker B.N., Fall P., Hall C., et al. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am J Kidney Dis. 1993;22(4):611-15. Doi: 10.1016/ s0272-6386(12)80939-5. 64. Wirth G.J., Teuscher J., Graf J.D., Iselin C.E. Efavirenz-induced urolithiasis. Urol Res. 2006;34(4):288-89. Doi: 10.1007/s00240- 006-0052-6.
Автор для связи: Ольга Дмитриевна Остроумова, д.м.н., профессор, зав. кафедрой терапии и полиморбидной патологии, Российская медицин¬ская академия непрерывного профессионального образования; профессор кафедры клинической фармакологии и пропедевтики внутренних болезней, Первый Московский государственный медицинский университет им. И. М. Сеченова (Сеченовский Университет), Москва, Россия; ostroumova.olga@mail.ru ORCID / eLibrary SPIN:
А.И. Листратов (Listratov A.I.), https://orcid.org/0000-0002-0401-1132
О.Д. Остроумова (Ostroumova O.D.), https://orcid.org/0000-0002-0795-8225; eLibrary SPIN: 3910-6585
А.Г. Комарова (Komarova A.G.), https://orcid.org/0000-0002-8633-7012